Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvectis Pharma, Inc.NVCT · Entity 5166 | Chief Science & Business Off | January 06, 2026 | January 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvectis Pharma, Inc.
Report date January 06, 2026 · Filed January 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,806,319 |
Reported balance
After 2026-01-06 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-01-06 · Grant · Acquired 150,000 · Balance 1,806,319 F1: The 150,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Poradosu's continued service on such dates. F2: Includes shares of restricted common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The 150,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Poradosu's continued service on such dates.
F2: Includes shares of restricted common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 06, 2026 Filed Jan 9, 2026 16:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-002497 · tm262288-2_4seq1.xml · nonDerivative · entry 1 Poradosu Enrique · CIK 0001898147 · Chief Science & Business Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,806,319 F1 · shares: The 150,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Poradosu's continued service on such dates. F2 · balance_after: Includes shares of restricted common stock. Read SEC document |
| January 02, 2025 Filed Jan 3, 2025 18:12 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-000912 · tm251747-3_4seq1.xml · nonDerivative · entry 1 Poradosu Enrique · CIK 0001898147 · Chief Science & Business Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,656,319 F1 · shares: The 150,000 shares of restricted Common Stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Poradosu's continued service on such dates. F2 · balance_after: Includes 503,399 shares of restricted stock. Read SEC document |
| November 19, 2024 Filed Nov 20, 2024 08:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 2,000 | $4.99 | $9,980.00 |
DisclosureSEC source: 0001104659-24-120876 · tm2428944-1_4seq1.xml · nonDerivative · entry 1 Poradosu Enrique · CIK 0001898147 · Chief Science & Business Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,506,319 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $4.98 to $4.99. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 353,399 shares of restricted stock. Read SEC document |
| May 10, 2024 Filed May 13, 2024 08:49 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 500 | $6.29 | $3,145.00 |
DisclosureSEC source: 0001104659-24-060262 · tm2414233-2_4seq1.xml · nonDerivative · entry 1 Poradosu Enrique · CIK 0001898147 · Chief Science & Business Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,504,319 F1 · balance_after: Includes 353,399 shares of restricted stock. Read SEC document |
| January 03, 2024 Filed Jan 5, 2024 16:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 130,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-001825 · tm242141-2_4seq1.xml · nonDerivative · entry 1 Poradosu Enrique · CIK 0001898147 · Chief Science & Business Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,503,819 F1 · shares: The restricted stock will vest according to the following schedule: one-third on each of 01/3/2025, 01/3/2026, and 01/3/2027. F2 · balance_after: Includes 353,399 shares of restricted stock. Read SEC document |
| March 27, 2023 Filed Mar 28, 2023 08:30 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 500 | $11.55 | $5,775.00 |
DisclosureSEC source: 0001104659-23-037421 · tm2310693-1_4seq1.xml · nonDerivative · entry 1 Poradosu Enrique · CIK 0001898147 · Chief Science & Business Off 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,373,819 F1 · balance_after: Includes 48,399 shares of restricted stock and 175,000 restricted stock units. Read SEC document |
| January 12, 2023 Filed Jan 13, 2023 17:05 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 115,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-23-003866 · tm232835-3_4seq1.xml · nonDerivative · entry 1 Poradosu Enrique · CIK 0001898147 · Chief Science & Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,373,319 F1 · shares: The restricted stock units will vest according to the following schedule: one-third on each of 01/12/2024, 01/12/2025, and 01/12/2026. F2 · balance_after: Includes 48,399 shares of restricted stock and 175,000 restricted stock units. Read SEC document |
| May 12, 2022 Filed May 16, 2022 08:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 300 | $16.04 | $4,812.00 |
DisclosureSEC source: 0001104659-22-060908 · tm2215423-1_4seq1.xml · nonDerivative · entry 2 Poradosu Enrique · CIK 0001898147 · Chief Science & Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,258,319 F3 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $15.99 to $16.08. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 48,399 shares of restricted stock and 60,000 restricted stock units. Read SEC document |
| May 12, 2022 Filed May 16, 2022 08:31 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock | 370 | $14.76 | $5,461.20 |
DisclosureSEC source: 0001104659-22-060908 · tm2215423-1_4seq1.xml · nonDerivative · entry 1 Poradosu Enrique · CIK 0001898147 · Chief Science & Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,258,019 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $14.60 to $15.05. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 48,399 shares of restricted stock and 60,000 restricted stock units. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 16:46 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-22-042815 · tm2211420-3_4seq1.xml · nonDerivative · entry 1 Poradosu Enrique · CIK 0001898147 · Chief Science & Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,257,649 F1 · shares: The restricted stock units will vest according to the following schedule: one-third on each of 4/1/2023, 4/1/2024, and 4/1/2025. F2 · balance_after: Includes 48,399 shares of restricted stock and 60,000 restricted stock units. Read SEC document |
| February 07, 2022 Filed Feb 8, 2022 18:01 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock, par value $0.00001 | 800 | $3.88 | $3,104.00 |
DisclosureSEC source: 0001104659-22-014376 · tm225864-3_4seq1.xml · nonDerivative · entry 2 Poradosu Enrique · CIK 0001898147 · Chief Science & Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,197,649 F3 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $3.45 to $3.98. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F4 · balance_after: Includes 48,399 shares of restricted stock. Read SEC document |
| February 04, 2022 Filed Feb 8, 2022 18:01 UTC | Nuvectis Pharma, Inc. NVCT · Entity 5166 | PurchaseCommon Stock, par value $0.00001 | 3,800 | $3.35 | $12,730.00 |
DisclosureSEC source: 0001104659-22-014376 · tm225864-3_4seq1.xml · nonDerivative · entry 1 Poradosu Enrique · CIK 0001898147 · Chief Science & Business Off 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,196,849 F1 · price: Reflects the weighted average purchase price. The range of prices for the shares purchased was $3.25 to $3.43. The reporting person effected multiple same-way open market purchase transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one-dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares purchased at each separate price. F2 · balance_after: Includes 48,399 shares of restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.